BIO-Europe® 2016: Karus CEO highlights niche indications for oncology innovation

November 22, 2016
Karus Therapeutics CEO, Simon Kerry, talks to Scrip senior writer, Lucie Ellis, during the recent BIO-Europe® partnering meeting about the company’s cancer-focused pipeline and where its products will sit within the crowded oncology market space. Kerry highlights Karus' strategy of targeting niche cancer indications and outlines how the smaller biotech will compete with big pharma businesses active in oncology drug development.
Previous Video
BIO-Europe® 2016: BioNTech's Sean Marett explains Genentech deal rationale
BIO-Europe® 2016: BioNTech's Sean Marett explains Genentech deal rationale

Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Inform...

Next Video
BIO-Europe® 2016: F-star business chief discuss Denali deal and potential F-star delta spinout
BIO-Europe® 2016: F-star business chief discuss Denali deal and potential F-star delta spinout

Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global di...